Is Survodutide Approved Yet?

Is Survodutide FDA Approved?

No. As of March 9, 2026, survodutide has not been approved by the FDA or any other regulatory agency worldwide. The drug is currently in Phase 3 clinical trials under Boehringer Ingelheim’s SYNCHRONIZE program for obesity and the SYMPHONY program for MASH. No New Drug Application (NDA) has been filed.

Boehringer Ingelheim has not publicly disclosed an NDA submission date. Based on the Phase 3 timeline — with SYNCHRONIZE results expected in 2026 — the earliest realistic window for an NDA filing is 2027, with a potential FDA decision in late 2027 or 2028.

What is Survodutide?

Survodutide (BI 456906) is Boehringer Ingelheim’s once-weekly injectable dual agonist targeting both the GLP-1 receptor and the glucagon receptor. This dual mechanism is the core differentiator. While GLP-1 receptor activation reduces appetite and slows gastric emptying — the same pathway used by semaglutide and tirzepatide — glucagon receptor activation adds two distinct pharmacological effects: increased energy expenditure and improved hepatic lipid metabolism.

The glucagon component is what separates survodutide from the current generation of approved obesity drugs. Glucagon receptor activation may help preserve lean muscle mass during weight loss, a significant concern with GLP-1-only therapies where a portion of weight lost comes from lean tissue rather than fat. The dual mechanism also positions survodutide for metabolic dysfunction-associated steatohepatitis (MASH), where the glucagon pathway directly addresses liver fat accumulation. For a detailed mechanistic overview, see our survodutide dual agonist compound profile.

What Does the Phase 2 Data Show?

In Phase 2 trials, the highest dose of survodutide produced approximately 19% body weight loss at 46 weeks. This figure is notable because the trial duration was shorter than many comparable obesity trials — the standard Phase 3 obesity trial typically runs 68–76 weeks.

The Phase 2b data in MASH were equally significant. Survodutide demonstrated substantial liver fat reduction, with MASH resolution achieved in approximately 64% of patients. These liver-specific outcomes differentiate survodutide from GLP-1-only drugs and support the mechanistic rationale for dual GLP-1/glucagon agonism in metabolic liver disease.

Phase 2 results are directional rather than definitive. The sample sizes are smaller, the trial durations are shorter, and the populations may not fully represent the Phase 3 populations. The SYNCHRONIZE Phase 3 program will provide the larger-scale, longer-duration data needed for regulatory submission. For context on where survodutide fits among other pipeline candidates, see our best research peptides guide for 2026.

What is the SYNCHRONIZE Phase 3 Program?

SYNCHRONIZE is Boehringer Ingelheim’s Phase 3 clinical program evaluating survodutide for obesity. The program includes multiple trials designed to generate the safety and efficacy data required for regulatory submissions.

SYNCHRONIZE-1 is a 76-week trial evaluating survodutide for weight management. Results are expected in 2026.

SYNCHRONIZE-2 is a 76-week trial enrolling 752 participants across 133 clinical sites in 19 countries. The multinational scope of this trial reflects the global regulatory strategy. Results are also expected in 2026.

If Phase 3 results confirm the Phase 2 efficacy signal, Boehringer Ingelheim could file an NDA with the FDA in 2027 at the earliest. An FDA approval decision would then follow in 2028 at the earliest, assuming a standard review timeline.

When Could Survodutide Be Approved?

The realistic timeline depends on Phase 3 outcomes. If the SYNCHRONIZE results reported in 2026 are positive, Boehringer Ingelheim could file an NDA with the FDA in 2027. Assuming a standard 10–12-month FDA review cycle, a potential approval decision could come in late 2027 or 2028.

Several factors could accelerate or delay this timeline. Positive Phase 3 data that clearly demonstrate both efficacy and safety could support a faster regulatory path. Conversely, any safety signals, requests for additional data, or manufacturing questions could extend the review process. See our survodutide vs retatrutide comparison for a side-by-side analysis of these two glucagon-engaging compounds.

Boehringer Ingelheim has not publicly confirmed an NDA filing date. Until Phase 3 data are reported and the company discloses its regulatory strategy, all timelines remain estimates. Track every major milestone on our obesity drug approval tracker for 2026.

What About MASH?

Survodutide is also being evaluated for MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) in the Phase 3 SYMPHONY program. This is a separate regulatory path from the obesity program.

The MASH data from Phase 2b were among the strongest reported for any investigational drug in this space. Approximately 64% of patients achieved MASH resolution, and significant reductions in liver fat were observed across dose groups. The glucagon receptor component of survodutide is thought to directly address hepatic lipid metabolism, which is central to MASH pathology.

If the SYMPHONY Phase 3 program confirms these results, survodutide could become one of the first drugs approved specifically for MASH — a condition with limited approved treatment options. The MASH indication represents a distinct commercial opportunity beyond obesity. For a broader look at next-generation obesity agents, see our retatrutide vs tirzepatide vs CagriSema comparison.